JP2024510260A5 - - Google Patents
Info
- Publication number
- JP2024510260A5 JP2024510260A5 JP2023556949A JP2023556949A JP2024510260A5 JP 2024510260 A5 JP2024510260 A5 JP 2024510260A5 JP 2023556949 A JP2023556949 A JP 2023556949A JP 2023556949 A JP2023556949 A JP 2023556949A JP 2024510260 A5 JP2024510260 A5 JP 2024510260A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- acth
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025157498A JP2026009936A (ja) | 2021-03-19 | 2025-09-22 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163310P | 2021-03-19 | 2021-03-19 | |
| US63/163,310 | 2021-03-19 | ||
| US202263298571P | 2022-01-11 | 2022-01-11 | |
| US63/298,571 | 2022-01-11 | ||
| PCT/US2022/020543 WO2022197798A1 (en) | 2021-03-19 | 2022-03-16 | Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025157498A Division JP2026009936A (ja) | 2021-03-19 | 2025-09-22 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510260A JP2024510260A (ja) | 2024-03-06 |
| JP2024510260A5 true JP2024510260A5 (https=) | 2025-10-01 |
Family
ID=83321094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556949A Pending JP2024510260A (ja) | 2021-03-19 | 2022-03-16 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
| JP2025157498A Pending JP2026009936A (ja) | 2021-03-19 | 2025-09-22 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025157498A Pending JP2026009936A (ja) | 2021-03-19 | 2025-09-22 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12280046B2 (https=) |
| EP (1) | EP4308553A4 (https=) |
| JP (2) | JP2024510260A (https=) |
| KR (1) | KR20230159443A (https=) |
| AU (1) | AU2022240609A1 (https=) |
| BR (1) | BR112023018816A2 (https=) |
| CA (1) | CA3211644A1 (https=) |
| IL (1) | IL305952A (https=) |
| MX (1) | MX2023010897A (https=) |
| WO (1) | WO2022197798A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019280689B2 (en) | 2018-06-05 | 2024-09-05 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof |
| AU2022240609A1 (en) | 2021-03-19 | 2023-09-28 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease |
| CN120344523A (zh) * | 2022-12-16 | 2025-07-18 | 克林提克斯医药股份有限公司 | 结晶黑皮质素亚型-2受体(mc2r)拮抗剂 |
| WO2024242979A1 (en) * | 2023-05-19 | 2024-11-28 | Crinetics Pharmaceuticals, Inc. | Compositions and methods for the treatment of congenital adrenal hyperplasia |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284956A (en) | 1988-09-06 | 1994-02-08 | Hoffmann-La Roche Inc. | Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines |
| WO1999064002A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| US6890940B2 (en) | 2001-06-29 | 2005-05-10 | Kowa Co., Ltd. | Bis(2-aryl-5-pyridyl) derivatives |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| EP1465867A1 (en) | 2001-10-09 | 2004-10-13 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| KR20040058307A (ko) | 2001-11-26 | 2004-07-03 | 쉐링 코포레이션 | 비만 및 ｃｎｓ 장애를 치료하기 위한 피페리딘계 ｍｃｈ길항제 |
| US7105489B2 (en) | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| AU2003216274A1 (en) | 2002-02-11 | 2003-09-04 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
| AU2003230367A1 (en) | 2002-05-10 | 2003-11-11 | Neurocrine Biosciences, Inc. | Substituted piperazine as melanocortin receptors ligands |
| WO2004081643A1 (en) | 2002-12-20 | 2004-09-23 | Kaiser Aerospace & Electronics Corp. | Lenslet array with polarization conversion |
| EP1460073A1 (en) | 2003-03-20 | 2004-09-22 | MyoContract Ltd. | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| RS53252B (sr) | 2003-08-11 | 2014-08-29 | F.Hoffmann-La Roche Ag. | Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| CN1874777B (zh) | 2003-09-09 | 2012-07-04 | 弗·哈夫曼-拉罗切有限公司 | 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物 |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| US20050192286A1 (en) | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| US20050119252A1 (en) | 2003-10-22 | 2005-06-02 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| AU2006304305B2 (en) | 2005-10-18 | 2010-04-01 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| RU2303597C1 (ru) | 2006-05-12 | 2007-07-27 | Иващенко Андрей Александрович | Фармацевтическая композиция, способы ее получения и применения |
| HRP20100516T1 (hr) | 2006-09-20 | 2010-10-31 | Eli Lilly And Company | Tiazolpirazolopirimidini kao antagonisti receptora crf1 |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| PL2344474T3 (pl) | 2008-09-02 | 2016-03-31 | Novartis Ag | Pochodne pikolinamidu jako inhibitory kinaz |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI598337B (zh) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| WO2012163354A1 (en) | 2011-05-31 | 2012-12-06 | Linak A/S | Actuator |
| EP4691556A3 (en) | 2014-12-19 | 2026-04-29 | H. Lundbeck A/S | Humanized anti-acth antibodies and use thereof |
| EP3199156A1 (de) | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika |
| WO2018003962A1 (ja) | 2016-06-30 | 2018-01-04 | 国立研究開発法人理化学研究所 | 新規化合物又はその薬理学的に許容される塩 |
| WO2019014460A1 (en) | 2017-07-12 | 2019-01-17 | The Brigham And Women's Hospital, Inc. | MOLECULES ENHANCING EAAT2 |
| SG11202003407VA (en) | 2017-10-17 | 2020-05-28 | Merck Patent Gmbh | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF |
| AU2019280689B2 (en) | 2018-06-05 | 2024-09-05 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof |
| US20220023266A1 (en) | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| US12479825B2 (en) | 2019-11-07 | 2025-11-25 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof |
| CA3164117A1 (en) | 2019-12-18 | 2021-06-24 | Crinetics Pharmaceuticals, Inc. | Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| ES3032933T3 (en) | 2019-12-23 | 2025-07-29 | Crinetics Pharmaceuticals Inc | Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| KR20240023691A (ko) | 2020-08-12 | 2024-02-22 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
| AU2022240609A1 (en) | 2021-03-19 | 2023-09-28 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease |
| WO2023163945A1 (en) | 2022-02-23 | 2023-08-31 | Crinetics Pharmaceuticals, Inc. | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome |
| CN120344523A (zh) | 2022-12-16 | 2025-07-18 | 克林提克斯医药股份有限公司 | 结晶黑皮质素亚型-2受体(mc2r)拮抗剂 |
-
2022
- 2022-03-16 AU AU2022240609A patent/AU2022240609A1/en active Pending
- 2022-03-16 BR BR112023018816A patent/BR112023018816A2/pt unknown
- 2022-03-16 MX MX2023010897A patent/MX2023010897A/es unknown
- 2022-03-16 WO PCT/US2022/020543 patent/WO2022197798A1/en not_active Ceased
- 2022-03-16 EP EP22772124.8A patent/EP4308553A4/en active Pending
- 2022-03-16 IL IL305952A patent/IL305952A/en unknown
- 2022-03-16 KR KR1020237032584A patent/KR20230159443A/ko active Pending
- 2022-03-16 JP JP2023556949A patent/JP2024510260A/ja active Pending
- 2022-03-16 CA CA3211644A patent/CA3211644A1/en active Pending
- 2022-03-16 US US17/696,279 patent/US12280046B2/en active Active
-
2025
- 2025-03-18 US US19/082,571 patent/US20250367190A1/en active Pending
- 2025-09-22 JP JP2025157498A patent/JP2026009936A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024510260A5 (https=) | ||
| CN1103589C (zh) | 调节人体性反应的方法 | |
| TWI619505B (zh) | 脫毛症治療劑 | |
| Krasagakis et al. | Management of severe scleroderma with long-term extracorporeal photopheresis | |
| JP2026035701A5 (https=) | ||
| JP2017533972A5 (https=) | ||
| JP2024500324A5 (https=) | ||
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JPH07556B2 (ja) | 間質性膀胱炎に対する治療用医薬組成物 | |
| Buckle | Treatment of thyroid crisis by beta-adrenergic blockade | |
| JP2001526686A (ja) | ヒトの性応答を調節するための組み合わせ治療 | |
| BR112020018362A2 (pt) | Composição de glp-1 para tratar obesidade e controle de peso | |
| JP2022058873A5 (https=) | ||
| JP2017522389A (ja) | シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療 | |
| WO2020175817A1 (ko) | 섬유증의 예방, 개선 또는 치료용 조성물 | |
| TAUBENHAUS et al. | Clinical and histological observations on a case of scleroderma treated with cortisone | |
| US20190192421A1 (en) | Oral transmucosal compositions including aromatase inhibitors for low testosterone levels in men | |
| BARNES et al. | Effect of cortisone and corticotropin (ACTH) on the acute phase of rheumatic fever: further observations | |
| JP2001512482A (ja) | レプチン受容体リガンドの拍動性送達 | |
| JP4652689B2 (ja) | 骨再生を促進するカルモジュリンの使用 | |
| Finkler | Initial priapism during therapy with testosterone propionate in a eunuchoid man | |
| AU781842B2 (en) | Use of growth hormone (hGH) for the treatment of sexual functional disturbances | |
| JP2024518804A5 (https=) | ||
| JP2003534237A (ja) | 食欲の抑制又は満腹の惹起のための成長ホルモン又は成長ホルモン分泌促進物質の使用 | |
| JP5667565B2 (ja) | 閉経期、ホルモン変動および関節炎と関連する症状を治療するための組成物および方法 |